The Library
Decreased plasma omentin-1 levels in Type 1 diabetes mellitus
Tools
Tools
Tools
Tan, Bee K., Pua, S., Syed, Farhatullah, Lewandowski, K. C., O'Hare, J. Paul and Randeva, Harpal S. (2008) Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabetic Medicine, Vol.25 (No.10). pp. 1254-1255. ISSN 0742-3071
Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/j.1464-5491.2008.02568.x
Abstract
Context:The novel adipokine, nesfatin-1/NUCB-2, reduces food intake, levels of which are elevated in overweight individuals. Objectives:The aim of the study was to investigate the mechanisms underlying brain nesfatin-1/NUCB-2 uptake and to determine whether reduced uptake may contribute to nesfatin-1/NUCB-2 resistance. Design:Cerebrospinal fluid (CSF) and corresponding plasma nesfatin-1/NUCB-2 were measured by ELISA [18 men and 20 women; age, 19–80 yr; body mass index (BMI), 16.2–38.1 kg/m2] and correlated to body adiposity and metabolic parameters. Results:CSF/plasma nesfatin-1/NUCB-2 ratio was significantly negatively associated with BMI, body weight, fat mass, and CSF glucose. BMI was predictive of CSF/plasma nesfatin-1/NUCB-2 ratio (β = −0.786; P = 0.045). CSF nesfatin-1/NUCB-2 was significantly positively associated with plasma nesfatin-1/NUCB-2 (R = 0.706; P < 0.01). There was a significant linear relation between CSF and plasma nesfatin-1/NUCB-2 in lean (BMI <25 kg/m2; R = 0.744; P = 0.002) and obese (BMI ≥30 kg/m2; R = 0.693; P = 0.026) subjects. Subjects in the highest plasma nesfatin-1/NUCB-2 quintile had lower CSF/plasma nesfatin-1/NUCB-2 ratio [26.5% (26.0–29.5%)] compared to the lowest plasma nesfatin-1/NUCB-2 quintile [38.5% (34.0–42.0%)] (P < 0.01), corresponding BMI [32.4 (31.0–35.0) vs. 23.3 (19.7–23.5) kg/m2; P < 0.01], and fat mass [32.8 (29.5–40.6) vs. 30.7 (8.2–20.1) kg/m2; P < 0.01]. Conclusions:Our observations have important implications with respect to the potential weight-reducing actions of nesfatin-1/NUCB-2 treatment. Future research should seek to clarify whether nesfatin-1/NUCB-2 would be beneficial in the management of obesity.
| Item Type: | Journal Item |
|---|---|
| Subjects: | R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine > Warwick Medical School > Clinical Sciences Research Institute (CSRI) Faculty of Medicine > Warwick Medical School |
| Library of Congress Subject Headings (LCSH): | Diabetes, Insulin resistance, Adipose tissues |
| Journal or Publication Title: | Diabetic Medicine |
| Publisher: | Wiley-Blackwell Publishing Ltd. |
| ISSN: | 0742-3071 |
| Date: | October 2008 |
| Volume: | Vol.25 |
| Number: | No.10 |
| Number of Pages: | 3 |
| Page Range: | pp. 1254-1255 |
| Identification Number: | 10.1111/j.1464-5491.2008.02568.x |
| Status: | Peer Reviewed |
| Publication Status: | Published |
| Access rights to Published version: | Restricted or Subscription Access |
| Funder: | General Charities of the City of Coventry |
| References: | 1 Gualillo O, González-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007; 17 : 275– 283. 2 Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N et al . Evidence of increased inflammation and microcirculatory abnormalities in patients with Type 1 diabetes and their role in microvascular complications. Diabetes 2007; 56 : 2790–2796. 3 Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H et al . Omentin-1, a novel adipokine, is decreased in overweight insulin resistant women with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57 : 801–808. 4 Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC et al . Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290 : E1253– E1261. 5 Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H et al . Elevated serum concentration of adipose-derived factor, adiponectin, in patients with Type 1 diabetes. Diabetes Care 2002; 25 : 1665–1666. 6 Peake PW, Kriketos AD, Denyer GS, Campbell LV, Charlesworth JA. The postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant subjects. Int J Obes Relat Metab Disord 2003; 27 : 657–662. |
| URI: | http://wrap.warwick.ac.uk/id/eprint/29308 |
Data sourced from Thomson Reuters' Web of Knowledge
Actions (login required)
 |
View Item |
